|Bid||0.0000 x 1100|
|Ask||0.0000 x 1800|
|Day's Range||0.7710 - 0.7949|
|52 Week Range||0.6700 - 1.5500|
|Beta (3Y Monthly)||1.84|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 14, 2017 - Aug 18, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.02|
Interpace Diagnostics Group, Inc. (IDXG) announced today that it has closed on a $13 million Convertible Preferred Stock investment by Ampersand Capital Partners (Ampersand). This investment constitutes the second tranche of the overall $27 million Convertible Preferred Stock financing provided by Ampersand to Interpace in connection with the Company’s July 15, 2019 acquisition of the BioPharma Business of Cancer Genetics, Inc. (CGIX). The condition surrounding the second tranche financing was approved by Interpace shareholders which was obtained at the Annual Shareholder Meeting on October 10, 2019.
The big shareholder groups in Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) have power over the company...
Interpace Diagnostics Group, Inc. (IDXG) announced today that it has been named one of the 50 Most Admired Companies of the Year by The Silicon Review. The honorees are chosen by The Silicon Review’s editorial board recognizing companies whose industry achievements break new technological ground and who’s company cultures and values represent a commitment to innovation. “We are pleased to be recognized by The Silicon Review as one of the 50 Most Admired Companies as we continue to push the envelope in providing diagnostic tests and biopharma services to help assess the risk of cancer progression and select the best treatment for patients”, said Jack Stover, CEO of Interpace.
Interpace Diagnostics Group, Inc. (IDXG) announced today that it has contracted with 3 independent Blue Cross Blue Shield (BCBS) plans totaling nearly 5 million covered lives across Alabama, Arkansas, and Arizona. The ThyGeNEXT® - ThyraMIR® combination represents the first and only test on the market that includes the rule-out properties of next-generation sequencing of a patient’s DNA and RNA along with the rule-in capabilities of a micro-RNA classifier to provide physicians with clinically actionable test results. According to the American Cancer Society, thyroid cancer is the most rapidly increasing cancer in the U.S., tripling in the past three decades.
PARSIPPANY, NJ, Sept. 18, 2019 -- Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced that the Company will present at the upcoming.
Interpace Diagnostics Group, Inc.’s subsidiary, Interpace BioPharma Inc. (“Interpace”, “Interpace BioPharma” or the “Company”) today announced that it has entered into a partnership agreement to jointly develop, promote, and offer translational studies and clinical trial solutions to biotech and pharmaceutical companies with Genecast (Beijing) Biotechnology Co. Ltd (“Genecast”) of the Peoples Republic of China (“PRC”). Genecast is a leader in offering diagnostic products and services in the field of oncology and providing a wide range of diagnostic services to pharmaceutical and biotech companies in the PRC.
PARSIPPANY, NJ, Sept. 06, 2019 -- Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced that the Company will present at the upcoming.
MINNEAPOLIS, Aug. 19, 2019 -- Predictive Oncology Inc., (NASDAQ: POAI) (“Predictive Oncology ” or “the Company”) an artificial intelligence (AI) and data-driven functional.
Second Quarter Revenue Grew 14% Over the Prior Year and 19% Year to Date Over the Prior Year Acquired Growing BioPharma Services Business Net Revenue Guidance Increased.
NEW YORK, NY / ACCESSWIRE / August 13, 2019 / Interpace Diagnostics Group, Inc. (NASDAQ: IDXG ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 13, ...
PARSIPPANY, NJ, Aug. 06, 2019 -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it will report its second quarter 2019 financial results on Tuesday,.
Interpace Diagnostics Group, Inc. (IDXG) announced today that it has contracted with Blue Cross Blue Shield (BCBS) of Michigan, a not-for-profit independent member of the Blue Cross Blue Shield Association with 4.5 million members in the State of Michigan, making it the largest payer in the State, along with another 1.6 million members across multiple other States. The contract makes the ThyGeNEXT® and ThyraMIR® tests both covered services as well as in-network services for their total of 6 million members.
Interpace Diagnostics Group, Inc. (IDXG) announced today that it has entered in to a contract with Blue Shield of California, a not-for-profit independent member of the Blue Cross Blue Shield Association making ThyGeNEXT and ThyraMIR tests in-network services for their 4 million lives. Blue Shield originally granted coverage for ThyGeNEXT and ThyraMIR in March of 2018 and now members will be able to access Interpace’s molecular thyroid tests on an in-network basis, which will limit their out of pocket expenses and optimize their benefits in accordance with their in-network benefit levels. According to the American Cancer Society, thyroid cancer is the most rapidly increasing cancer in the U.S., tripling in the past three decades.
Interpace Diagnostics Group, Inc. (IDXG) announced today that it has reached an agreement with SelectHealth (a plan associated with Intermountain Healthcare) to provide its proprietary thyroid cancer assays, ThyGeNEXT® and ThyraMIR® to SelectHealth’s more than 850,000 members in Utah and Idaho. Physicians across SelectHealth’s entire network will now be able to utilize Interpace’s thyroid tests to assess indeterminate thyroid nodules thereby providing physicians with additional diagnostic options.
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced it completed an agreement with the Helomics division of Predictive Oncology (NASDAQ: POAI), which is focused on applying artificial intelligence to personalized medicine and drug discovery. It's estimated that the treatment market for thyroid cancer was valued at approximately $340 million in 2018 and is expected to reach $2.1 billion by the end of 2025. Under the agreement, the companies will develop products to diagnose and assess the risk for thyroid cancer as well as provide appropriate therapeutic recommendations.
Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or the “Company), announced today that it has executed an agreement with the Helomics division of Predictive Oncology (NASDAQ:POAI), a company focused on applying artificial intelligence to personalized medicine and drug discovery. As part of this agreement, the Companies expect to develop a pipeline of products that work seamlessly together to diagnose and assess the risk for thyroid cancer as well as provide appropriate therapeutic recommendations by leveraging Interpace’s Thyroid products, ThyGeNEXT® and ThyraMIR®, coupled with Helomics’ patient-derived tumor profiling and AI platform known as “D-CHIP.” Under the plan for this phase of the agreement Helomics will build a model using Interpace’s existing clinical data which can be utilized to identify druggable targets for treatment of indolent and aggressive thyroid cancers.
Cancer Genetics (NASDAQ: CGIX ) shares are trading sharply higher after Interpace Diagnostics (NASDAQ: IDXG ) said it purchased the Biopharma Services unit of the Cancer Genetics. Interpace Diagnostics ...
Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or the “Company”), announced today that it has acquired assets and certain liabilities constituting the Biopharma Services business of Cancer Genetics, Inc. (CGIX) (the “BioPharma Business”) for approximately $23.5 million subject to certain adjustments. The acquisition is expected to create a leading oncology testing and service company in the clinical diagnostic and Biopharma markets, leveraging sophisticated assays, novel algorithms and custom service capabilities across the continuum of oncology from precancerous assessment to drug discovery and clinical trial support. In conjunction with this acquisition Ampersand Capital Partners, one of the leading private equity firms in the diagnostic/biopharma sector, agreed to invest $27M in Interpace in two tranches of newly issued convertible preferred stock, a portion of which will be subject to approval by Interpace’s shareholders.
Long term investing works well, but it doesn't always work for each individual stock. We really hate to see fellow...
Interpace Diagnostics Group, Inc. (IDXG) announced today that its ThyGeNEXT™ and ThyraMIR® tests for thyroid cancer are now covered by Independence Blue Cross (Independence), providing plan benefits coverage for its members who meet established medical criteria for the tests. Interpace’s testing is made available to its members by its strategic partner, LabCorp (LH), Independence’s primary lab services provider, through LabCorp’s Dianon Pathology specialty laboratory.
Interpace Diagnostics Group, Inc. (IDXG), a fully integrated bioinformatics and commercial molecular diagnostic company, today announced that Dr. Sydney D. Finkelstein, Interpace’s Chief Scientific Officer, will present at the World Congress on Thyroid Cancer, which is being held in Rome, Italy from June 20-22, 2019. The presentation will detail outcomes of a study with patients using Interpace’s ThyGenX® and ThyGeNEXT® in combination with microRNA (miRNA) testing in indeterminate thyroid nodules. “I am excited to present findings from Interpace’s thyroid study at the World Congress on Thyroid Cancer,” stated Dr. Sydney D. Finkelstein, Interpace’s Chief Scientific Officer.
Quarterly Revenue Grew to $6.0 Million, a 25% Increase Year-over-Year Annual 2019 Revenue Guidance of $27 to $28 Million, a 25% Increase Conference Call and Webcast.
PARSIPPANY, NJ, May 09, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (IDXG) announced today that data from an independent study, which showed that BarreGEN® performed effectively as a biomarker tool for predicting risk of developing more advanced stages of disease prior to visible appearance of advanced histology, will be presented at the annual Digestive Disease Week® (“DDW”). The meeting will be held in San Diego, CA on May 18-21, 2019, and is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.